Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   95004 News 


«12...236237238239240241242243244245246...10661067»
  • ||||||||||  remdesivir / Generic mfg., dexamethasone / Generic mfg., clopidogrel / Generic mfg.
    THERAPEUTIC CONSIDERATIONS IN COVID-19-ASSOCIATED ACUTE ISCHEMIC STROKE: A CASE SERIES (GALLERY) -  Nov 7, 2022 - Abstract #WSC2022WSC_1426;    
    Direct viral invasion, systemic inflammation (i.e., cytokine storm), endothelial dysfunction, and coagulation abnormalities contribute to the development of AIS in cases of COVID-19. Therefore in contrast to conventional AIS management, anticoagulation and glucocorticoid therapy plays an important role.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Guominkang formula alleviate inflammation in eosinophilic asthma by regulating immune balance of Th1/2 and Treg/Th17 cells. (Pubmed Central) -  Nov 5, 2022   
    The number of patients with allergic asthma is rising yearly, and hormonal drugs, such as dexamethasone, have unique advantages and certain limitations...Interestingly, we first found that DL-glutamine, L-pyroglutamic acid, prostaglandin b1, prostaglandin e2, and 3,4-dihydroxyhydrocinnamic acid are all associated with genus_Muriculum. GMK will be a new strategy for the treatment of eosinophilic asthma, and biomarkers will also be a new research direction.
  • ||||||||||  hydroxychloroquine / Generic mfg., methylprednisolone sodium succinate / Generic mfg., azathioprine / Generic mfg.
    Clinical, Journal:  Combined Central and Peripheral Demyelination in a Case With Sjogren Syndrome. (Pubmed Central) -  Nov 5, 2022   
    Our patient shows that patients with SS can have CCPD, and a significant clinical response can be obtained with early treatment. We hope that this unique case sheds light on the pathophysiology of CCPD.
  • ||||||||||  methylprednisolone sodium succinate / Generic mfg.
    Review, Journal:  How to Recognize and Manage Challenging DRESS Cases: Two Case Reports and A Review of the Literature. (Pubmed Central) -  Nov 5, 2022   
    Both cases presented with organ dysfunction and remained unresponsive to initial treatment with 1 mg/kg/day of intravenous methylprednisolone...Furthermore, we reviewed the literature in comparison with the present cases. In conclusion, plasmapheresis or pulse steroid therapy (250 mg/day of methylprednisolone for three days) can be used to treat difficult DRESS cases where organ failure is about to happen.
  • ||||||||||  Journal:  Perspectives on the advances in the pharmacotherapeutic management of Duchenne muscular dystrophy. (Pubmed Central) -  Nov 5, 2022   
    Corticosteroids such as prednisone and deflazacort are routinely given to patients to treat inflammation, but their use is limited by the occurrence of side effects and a lack of standardized prescribing...Excessive cost is a barrier to patients receiving medications that have yet to have established efficacy. Additional therapies have the potential to help patients with DMD, although most are several years away from approval for patient use.
  • ||||||||||  hydrocortisone / Generic mfg.
    Journal:  Modeling gene × environment interactions in PTSD using human neurons reveals diagnosis-specific glucocorticoid-induced gene expression. (Pubmed Central) -  Nov 5, 2022   
    Here, we compared transcriptional responses to hydrocortisone exposure in human induced pluripotent stem cell (hiPSC)-derived glutamatergic neurons and peripheral blood mononuclear cells (PBMCs) from combat veterans with PTSD (n = 19 hiPSC and n = 20 PBMC donors) and controls (n = 20 hiPSC and n = 20 PBMC donors)...We find evidence of a coregulated network of transcription factors that mediates glucocorticoid hyper-responsivity in PTSD. These findings suggest that induced neurons represent a platform for examining the molecular mechanisms underlying PTSD, identifying biomarkers of stress response, and conducting drug screening to identify new therapeutics.
  • ||||||||||  dexamethasone / Generic mfg.
    Biomarker, Journal, IO biomarker, Epigenetic controller:  Evaluation of cross-platform compatibility of a DNA methylation-based glucocorticoid response biomarker. (Pubmed Central) -  Nov 5, 2022   
    We developed an algorithm that reproduces the DNA methylation glucocorticoid response score using 450K data, increasing the accessibility for researchers to assess this biomarker in archived or publicly available datasets that use the 450K version of the Illumina BeadChip array. However, the NDMI850 and NDMI450 do not give similar results in cord blood, and due to data availability limitations, results from sample types of newborn cord blood should be interpreted with care.
  • ||||||||||  The Determination Trial Impact on Upfront (vs Delayed) Autologous Stem Cell Transplantation for Transplant-Eligible Newly Diagnosed Multiple Myeloma (ENMCC - Hall D) -  Nov 4, 2022 - Abstract #ASH2022ASH_6744;    
    P3
    Overall, our data show that OS (which was not a primary endpoint in DETERMINATION) is viewed as the most significant factor when considering 1L treatment decisions in NDMM, and less than half respondents indicated that PFS (a primary endpoint in DETERMINATION) persuaded them to increase their use of upfront, vs delayed, ASCT in their patients with transplant-eligible NDMM. Future research by the Cardinal Health Specialty Solutions will aim to clarify various aspect of novel therapies for NDMM including quadruplet 1L therapy, other anti-CD38 antibody upfront usage, minimal residual disease, and their respective impacts on the choice of upfront (vs delayed) ASCT consolidation in the 1L setting.
  • ||||||||||  dexamethasone / Generic mfg., prednisone / Generic mfg.
    Isolated Thrombocytopenia in Older Adults Is Associated with the Diagnosis of Hematologic Malignancy: A Population-Based Study (ENMCC - Hall D) -  Nov 4, 2022 - Abstract #ASH2022ASH_6684;    
    Among exposed patients, 378 (8.6%, 95% CI 7.8-9.5; 19.1/1000 person years (PY), 95% CI 17.1-21.0) were diagnosed with hematologic malignancy over 3.91 years of follow-up, compared to 204 unexposed patients (1.2%, 95% CI 1.0-1.3; 2.5/1000PY, 95% CI 2.2-2.8) over 4.05 years of follow-up. In the first year after consultation, the HR for being diagnosed with a hematologic malignancy was 15.5 (95% CI 11.3-21.4, p<0.0001, Figure 1) in exposed patients compared to unexposed.
  • ||||||||||  Darzalex (daratumumab) / J&J
    Effect of Daratumumab on Stem Cell Mobilization and Engraftment Kinetics Post Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma (ENMCC - Hall D) -  Nov 4, 2022 - Abstract #ASH2022ASH_6515;    
    As per institutional guidelines, a combination of granulocyte colony stimulating factor (GCSF) with plerixafor was used as the mobilizing regimen for patients >70 yrs; cyclophosphamide, etoposide and dexamethasone (CdE) with GCSF was used for patients <70...All patients received melphalan at a dose of 200mg/m2 administered intravenously on day -1...These observations are consistent with results published in two prior studies.5,6 Depending on the target goal for CD34+ cell collection, daratumumab should be used with caution in the upfront setting for multiple myeloma. This is particularly important if tandem stem cell transplantation, salvage transplantation, or stem cell boost post high dose therapy are being considered as prospective treatment options for patients with multiple myeloma.
  • ||||||||||  Darzalex (daratumumab) / J&J
    Dedalo: Phase II Study of Daratumumab Plus Pomalidomide and Dexamethasone (DPd) in Patients with Relapsed/Refractory Multiple Myeloma and 17p Deletion (ENMCC - Hall D) -  Nov 4, 2022 - Abstract #ASH2022ASH_6402;    
    P2
    Pts received continuous treatment with daratumumab (1800 mg subcutaneously or 16 mg/kg intravenously) weekly during cycles 1 and 2, every 2 weeks during cycles 3–6, and every 4 weeks thereafter; oral pomalidomide (4 mg, once daily on days 1–21); and oral or intravenous dexamethasone (40 mg once daily on days 1, 8, 15, and 22; 20 mg for those aged 75 years or older) at each 28-day cycle...Conclusion. In this difficult-to-treat population, DPd is a therapeutic option for pts of all ages and can be considered as a bridge to other immunotherapies.
  • ||||||||||  Ninlaro (ixazomib) / Takeda
    A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma (ENMCC - Hall D) -  Nov 4, 2022 - Abstract #ASH2022ASH_6397;    
    Median prior lines of therapy was 2 (range 1-4) with 100% of patients having prior treatment with lenalidomide, 97% with prior bortezomib and 13% prior daratumumab. Twice weekly ixazomib dosing in combination with pomalidomide and dexamethasone is a well-tolerated regimen with encouraging activity in a lenalidomide-refractory and high-risk RRMM population with a median PFS of 13 months.
  • ||||||||||  elranatamab (PF-06863135) / Pfizer
    Magnetismm-4: An Open Label, Phase 1B/2 Umbrella Study of Elranatamab in Combination with Other Anti-Cancer Treatments for Patients with Multiple Myeloma (ENMCC - Hall D) -  Nov 4, 2022 - Abstract #ASH2022ASH_6394;    
    P1, P1b/2,
    Phase 2 of SSA will further evaluate the efficacy and safety of the combination of elranatamab and nirogacestat...The dose escalation part of SSB is designed to assess the safety and tolerability of elranatamab in combination with lenalidomide and dexamethasone...In SSA, patients who received prior treatment with a BCMA-bispecific antibody are excluded, and in SSB, patients who received prior treatment with BCMA-directed therapy are excluded. The study is enrolling the Phase 1 portions and is being opened at multiple sites in the United States and Canada.